Old API Wind-down Ltd - Ordinary Shares ARLZQ

RE:RE:RE:RE:RE:RE:That's interesting...

[mjh9413]

I am uncertain what your statement "They never stated it has postive EBITDA" is really about but certainly they voiced it twice in the Toprol NR of Oct 4th, once in the italicized headline and in the text, namely: ;The transaction is expected to be immediately EBITDA accretive and to move profitability forward to 2017; and in the text they of course added "... in each case on an adjusted EBITDA basis."  The latter meaning adding back in not only those total interest costs but other non-EBITDA items, such as compensation adjustments etc. With Zack's estimates showing a negative EBITDA (not even adjusted EBITDA) we have confirmation of a serious reliance on Yosprala sales (which is the only reason I ever bought into ARZ before the Toprol deal was announced).
I agree with the other poster's comment "Why the rush?" and the only explanation I can think of is the significant increase they are planning in the sales force...selling not just the first focus,Yosprala, but as many othe heart-related compounds as possible. Again however this does not jibe with Adams saying AZ will sell Toprol for up to the first 9 mos after the deal is closed, adding another layer of expense. It is all a bit too 'bitty.' IMHO.